CDT

DallasNews Corporation Announces First Quarter 2024 Financial Results

Retrieved on: 
Mercoledì, Maggio 15, 2024
Preprint, Average cost, Return, Investment, CDT, Marketing, Publication, DallasNews Corporation, Total, Newsroom, Advertising, GAAP, Webcast, Video game

For the first quarter of 2024, on a non-GAAP basis, DallasNews reported an operating loss adjusted for certain items (“adjusted operating loss”) of $0.8 million, an improvement of $1.4 million or 64.0 percent when compared to an adjusted operating loss of $2.2 million reported in the first quarter of 2023.

Key Points: 
  • For the first quarter of 2024, on a non-GAAP basis, DallasNews reported an operating loss adjusted for certain items (“adjusted operating loss”) of $0.8 million, an improvement of $1.4 million or 64.0 percent when compared to an adjusted operating loss of $2.2 million reported in the first quarter of 2023.
  • Circulation revenue was $16.3 million in the first quarter of 2024, an increase of $0.3 million or 1.8 percent when compared to the $16.0 million reported for the first quarter of 2023.
  • Total consolidated operating expense in the first quarter of 2024, on a GAAP basis, was $32.9 million, an improvement of $5.1 million or 13.4 percent when compared to the first quarter of 2023.
  • DallasNews Corporation will conduct a conference call on Thursday, May 16, 2024, at 9:00 a.m. CDT to discuss financial results.

CDT Environmental Technology Investment Holdings Limited Files Annual Report on Form 20-F

Retrieved on: 
Mercoledì, Maggio 15, 2024
COVID-19, Jianyang District, CDT, Bank statement, Annual report, Growth, IPO, Lifting, Sewage

SHENZHEN, China, May 15, 2024 (GLOBE NEWSWIRE) -- CDT Environmental Technology Investment Holdings Limited (NASDAQ: CDTG) (“CDT”), a leading provider of waste treatment systems and services throughout China, today announces that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (the “SEC”) on May 15, 2024.

Key Points: 
  • SHENZHEN, China, May 15, 2024 (GLOBE NEWSWIRE) -- CDT Environmental Technology Investment Holdings Limited (NASDAQ: CDTG) (“CDT”), a leading provider of waste treatment systems and services throughout China, today announces that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (the “SEC”) on May 15, 2024.
  • The annual report on Form 20-F, which contains CDT’s audited consolidated financial statements, can be accessed through the SEC’s website at www.sec.gov or CDT’s website at https://www.cdthb.cn.
  • CDT will provide a hard copy of its annual report on Form 20-F, containing CDT’s audited consolidated financial statements, free of charge, to its shareholders upon request.
  • The midpoint of these ranges would represent growth of 30% for revenue and 35% for net income.

FibroBiologics Announces 2024 Annual Meeting of Stockholders

Retrieved on: 
Mercoledì, Maggio 15, 2024
Conditional sentence, CDT, Therapy, Shareholder, Fibroblast

HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2024 Annual Meeting of Stockholders will take place on August 27, 2024, at 11 a.m. CDT, exclusively through a virtual format.

Key Points: 
  • HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2024 Annual Meeting of Stockholders will take place on August 27, 2024, at 11 a.m. CDT, exclusively through a virtual format.
  • The record date for determination of stockholders entitled to vote at the annual meeting is July 1, 2024.

Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Mercoledì, Maggio 15, 2024
Patient, Survival, GMP, Holocene, Intelligence, Ovarian cancer, Science, Machine learning, HGSC, Solubility, CDT, EDT, Drug development, CLIA, Call, Conference, Marketing, Fujifilm, Research, Drug discovery, Biomarker, ASCO, Depreciation, UPMC Magee-Womens Hospital, UPMC, Hospital, Woman, Society, Therapy, Annual general meeting, Pharmaceutical industry

The company reported a net loss of approximately $4.2 million on total revenue of approximately $0.4 million for the quarter.

Key Points: 
  • The company reported a net loss of approximately $4.2 million on total revenue of approximately $0.4 million for the quarter.
  • General and administrative expenses increased to $2,627,076 in the first quarter of 2024 from $2,335,984 in the first quarter of 2023.
  • Operations expenses increased to $1,102,193 in the first quarter of 2024 compared to $878,518 in the first quarter of 2023.
  • Sales and marketing expenses increased to $739,734 in the first quarter of 2024 from $370,237 in the first quarter of 2023.

Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting

Retrieved on: 
Giovedì, Maggio 23, 2024
Research, Technology, Clinical Trials, Health Technology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Patient, Steroid, Pulmonary edema, Lymphocyte, Renal cell carcinoma, PD, Bladder cancer, Colorectal cancer, Clinical trial, CDT, Lung cancer, Head, Serum, NSCLC, Hypertelorism, Lymphocytopenia, Blood, Neoplasm, Avelumab, IL-2, Melanoma, MSI, ASCO, CD25, Poster, IL-6, Society, Artificial intelligence, Therapy, Hand, PD-L1, ADAS, Annual general meeting, MSS, CRS, RCC, Medical imaging

The data will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, Illinois.

Key Points: 
  • The data will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, Illinois.
  • The durability of the tumor reductions seen in several patients suggests the formation of immune memory of the cancerous cells.
  • “While other developmental IL-2 therapies focus on changing IL-2 itself, AU-007 is a human antibody that is a well-established therapeutic modality.
  • The Phase 2 expansion cohorts of the AU-007 study are continuing to enroll patients with a focus on melanoma and RCC.

TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany

Retrieved on: 
Giovedì, Maggio 23, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, GBM, Patient, Progression-free survival, Survival, TIGER, Toxicity, Clinical trial, CDT, Safety, Central nervous system, MD, General Hospital, Society, Cohort (statistics), Medical imaging

Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the treatment of patients with newly diagnosed glioblastoma (GBM) in Germany.

Key Points: 
  • Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the treatment of patients with newly diagnosed glioblastoma (GBM) in Germany.
  • The TIGER study enrolled 429 patients who used TTFields therapy between August 2017 and November 2019 and is the largest prospective, non-interventional study of the use of TTFields therapy in routine clinical care completed to date.
  • Median overall survival for patients treated with TTFields therapy was 19.6 months (95% CI, 17.9-22.4).
  • The outcomes observed in the TIGER study are consistent with the survival and safety results from Novocure’s phase 3 EF-14 clinical trial.

Enhabit Announces Participation in Upcoming Leerink Partners Healthcare Crossroads Conference 2024

Retrieved on: 
Lunedì, Maggio 20, 2024
Nursing, Health, Consumer, Seniors, Other Health, Managed Care, General Health, Conference, CDT

Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced its participation in the Leerink Partners Healthcare Crossroads Conference 2024.

Key Points: 
  • Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced its participation in the Leerink Partners Healthcare Crossroads Conference 2024.
  • Enhabit’s President and Chief Executive Officer Barbara Jacobsmeyer and Chief Financial Officer Crissy Carlisle will participate in a fireside chat on Wednesday, May 29, at 10 a.m. CDT.
  • The fireside chat will be webcast live and available for replay at https://investors.ehab.com.

NGL Energy Partners Announces Earnings Call

Retrieved on: 
Giovedì, Maggio 16, 2024
Energy, Transport, Logistics, Supply Chain Management, Oil, Gas, CDT, NGL, Webcast

NGL Energy Partners LP (NYSE: NGL) announced today that it plans to issue its fiscal year ended March 31, 2024 earnings press release post-market close on Thursday, June 6, 2024.

Key Points: 
  • NGL Energy Partners LP (NYSE: NGL) announced today that it plans to issue its fiscal year ended March 31, 2024 earnings press release post-market close on Thursday, June 6, 2024.
  • Members of NGL’s management team intend to host an earnings call following this release on Thursday, June 6, 2024 at 4:00 pm CDT to discuss its financial results.
  • Analysts, investors, and other interested parties may join the webcast via the event link: https://www.webcaster4.com/Webcast/Page/2808/50611 or by dialing (888) 506-0062 and providing access code: 410412.
  • An archived audio replay of the call will be available for 14 days, which can be accessed by dialing (877) 481-4010 and providing replay passcode 50611.

CyberArk to Host Investor Strategy Update at IMPACT 24: The Identity Security Conference on May 21, 2024

Retrieved on: 
Giovedì, Maggio 16, 2024
Online Privacy, Technology, Security, Professional Services, Business, Software, Networks, Internet, Data Management, Other Professional Services, CYBR, JW Marriott Hotels, Identity, CDT, IMPACT, Webcast, Keynote, Conference, Cryptocurrency

CyberArk (NASDAQ: CYBR ), the identity security company, today announced that it will host an Investor Strategy Update during CyberArk IMPACT 24: the Identity Security Conference.

Key Points: 
  • CyberArk (NASDAQ: CYBR ), the identity security company, today announced that it will host an Investor Strategy Update during CyberArk IMPACT 24: the Identity Security Conference.
  • Members of CyberArk’s executive team will discuss the company’s leadership position in identity security, our innovation roadmap, as well as market dynamics and our go-to-market approach.
  • The Investor Strategy Update will take place at the JW Marriott in Nashville, Tennessee on May 21, beginning at 10:30 am CDT.
  • The session will also be webcast live via the “Investor Relations” section of the company’s website at www.cyberark.com .

Royal Gold to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series on Wednesday, May 29, 2024

Retrieved on: 
Martedì, Maggio 14, 2024
Mining, Minerals, Natural Resources, MDT, CDT, EDT, Senior, Royal Gold, Acquisition, Business development, Google Chrome

To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.

Key Points: 
  • To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.
  • Royal Gold is a precious metals stream and royalty company engaged in the acquisition and management of precious metal streams, royalties, and similar production-based interests.
  • As of March 31, 2024, the Company owned interests on 177 properties on five continents, including interests on 37 producing mines and 24 development-stage projects.
  • Royal Gold is publicly traded on the Nasdaq Global Select Market under the symbol “RGLD.” The Company’s website is located at www.royalgold.com .